|
Market Closed -
Euronext Bruxelles
18:55:00 31/08/2026 +03
|
After hours 22:08:36 | |||
| 215.30 EUR | -0.55% |
|
214.80 | -0.23% |
| 08-20 | Cancer vaccines finally garner the spotlight |  |
| 08-19 | Danish Pharma H. Lundbeck Expects No Slowdown for Primary Growth Driver Brands | MT |
Company Valuation: UCB
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 18,947 | 13,973 | 14,969 | 36,464 | 45,333 | 41,278 | - | - |
| Change | - | -26.25% | 7.12% | 143.6% | 24.32% | -8.94% | - | - |
| Enterprise Value (EV) 1 | 19,807 | 15,973 | 17,146 | 37,918 | 45,326 | 41,588 | 39,473 | 36,902 |
| Change | - | -19.36% | 7.34% | 121.15% | 19.54% | -8.25% | -5.09% | -6.51% |
| P/E | 17.9x | 33.4x | 44.8x | 34.3x | 29.1x | 21.7x | 17.8x | 14.6x |
| PBR | 2.32x | 1.58x | 1.67x | 3.64x | 4.18x | 3.42x | 2.99x | 2.47x |
| PEG | - | -0.6x | -2.2x | 0x | 0.6x | 1x | 0.8x | 0.7x |
| Capitalization / Revenue | 3.28x | 2.53x | 2.85x | 5.93x | 5.86x | 4.75x | 4.26x | 3.83x |
| EV / Revenue | 3.43x | 2.9x | 3.26x | 6.16x | 5.86x | 4.79x | 4.08x | 3.43x |
| EV / EBITDA | 12.1x | 12.7x | 12.7x | 25.7x | 17.2x | 13.7x | 10.8x | 8.63x |
| EV / EBIT | 15x | 23.7x | 26.1x | 45.4x | 22.6x | 17x | 13.2x | 10.1x |
| EV / FCF | 15.6x | 18.4x | 38.5x | 41.2x | 24.6x | 21.8x | 14.9x | 11.8x |
| FCF Yield | 6.42% | 5.43% | 2.6% | 2.43% | 4.06% | 4.59% | 6.7% | 8.45% |
| Dividend per Share 2 | 1.3 | 1.33 | 1.36 | 1.39 | 1.45 | 1.457 | 1.502 | 1.534 |
| Rate of return | 1.3% | 1.81% | 1.72% | 0.72% | 0.61% | 0.67% | 0.69% | 0.71% |
| EPS 2 | 5.6 | 2.2 | 1.76 | 5.61 | 8.2 | 9.986 | 12.14 | 14.79 |
| Distribution rate | 23.2% | 60.5% | 77.3% | 24.8% | 17.7% | 14.6% | 12.4% | 10.4% |
| Net sales 1 | 5,777 | 5,517 | 5,252 | 6,152 | 7,741 | 8,690 | 9,684 | 10,764 |
| EBITDA 1 | 1,641 | 1,260 | 1,349 | 1,476 | 2,636 | 3,046 | 3,646 | 4,278 |
| EBIT 1 | 1,318 | 675 | 657 | 836 | 2,009 | 2,452 | 2,999 | 3,662 |
| Net income 1 | 1,058 | 418 | 343 | 1,065 | 1,558 | 1,925 | 2,327 | 2,827 |
| Net Debt 1 | 860 | 2,000 | 2,177 | 1,454 | -7 | 309.9 | -1,806 | -4,376 |
| Reference price 2 | 100.35 | 73.56 | 78.90 | 192.20 | 238.60 | 216.50 | 216.50 | 216.50 |
| Nbr of stocks (in thousands) | 188,812 | 189,959 | 189,721 | 189,720 | 189,996 | 190,663 | - | - |
| Announcement Date | 2/24/22 A | 2/22/23 A | 2/28/24 A | 2/27/25 A | 2/24/26 A | - | - | - |
1EUR in Million2EUR
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 21.68x | 4.79x | 13.66x | 0.67% | 47.9B | |
| 18.39x | 4.28x | 10.08x | 0.49% | 79.3B | |
| 20.35x | 4.33x | 13.36x | 2.44% | 59.21B | |
| -16.15x | 24.54x | -15.9x | -.--% | 55.09B | |
| 36.19x | 12.33x | 23.67x | -.--% | 49.86B | |
| 38.82x | 3.56x | 13.58x | -.--% | 32.28B | |
| 55.5x | 3.53x | 27.36x | -.--% | 25.21B | |
| 71.76x | 7.68x | 46.71x | -.--% | 23.87B | |
| 24.44x | 5.24x | 13.65x | -.--% | 16.89B | |
| 75.15x | 45.28x | 65.75x | 0.15% | 16.17B | |
| Average | 34.61x | 11.56x | 21.19x | 0.37% | 40.58B | |
| Weighted average by Cap. | 26.14x | 9.86x | 15.00x | 0.54% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- UCB Stock
- Valuation UCB
Select your edition
All financial news and data tailored to specific country editions
